person · Reporting owner

Treace John T.

Disclosed activity across 1 company

Tapewire entity: 20402
SEC CIK: 0001856380

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
TREACE MEDICAL CONCEPTS, INC.TMCI · Entity 5943	Director · Chief Executive Officer · 10% owner	August 20, 2026	August 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

TREACE MEDICAL CONCEPTS, INC.

Report date August 20, 2026 · Filed August 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,404,383	Last balance in matching sequence After 2026-08-24 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2026-08-20 · Purchase · Acquired 39,944 · Balance 7,388,383 F1: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3198 to $4.5048 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2: Includes 542,784 restricted stock units. Row 2 · 2026-08-21 · Purchase · Acquired 5,000 · Balance 7,393,383 F2: Includes 542,784 restricted stock units. Row 3 · 2026-08-24 · Purchase · Acquired 11,000 · Balance 7,404,383 F3: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3097 to $4.3489 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2: Includes 542,784 restricted stock units.
Common StockSEC Table I · non-derivative	IndirectBy spouse	1,605,000	Reported balance Holding disclosure · report date 2026-08-20 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 1,605,000 F4: The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee.
Common StockSEC Table I · non-derivative	IndirectBy spouse as trustee of a trust	1,471,250	Reported balance Holding disclosure · report date 2026-08-20 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 1,471,250 F4: The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee.
Common StockSEC Table I · non-derivative	IndirectAs trustee of a trust	1,839,063	Reported balance Holding disclosure · report date 2026-08-20 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 1,839,063 F5: The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.
Common StockSEC Table I · non-derivative	IndirectAs co-trustee of a trust	408,816	Reported balance Holding disclosure · report date 2026-08-20 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 408,816 F5: The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3198 to $4.5048 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

F2: Includes 542,784 restricted stock units.

F3: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3097 to $4.3489 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

F4: The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee.

F5: The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 22, 2021 Filed Dec 28, 2021 01:10 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	41,710	$16.29	$679,355.80	Disclosure SEC source: 0001567619-21-022542 · doc1.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,485,375 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.59 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 21, 2021 Filed Dec 23, 2021 00:05 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	3,537	$16.37	$57,893.97	Disclosure SEC source: 0001567619-21-022460 · doc1.xml · nonDerivative · entry 4 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,527,085 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.32 to $16.45 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 21, 2021 Filed Dec 23, 2021 00:05 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	34,047	$16.09	$547,649.40	Disclosure SEC source: 0001567619-21-022460 · doc1.xml · nonDerivative · entry 3 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,530,622 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.32 to $16.31 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 20, 2021 Filed Dec 23, 2021 00:05 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	600	$16.31	$9,784.02	Disclosure SEC source: 0001567619-21-022460 · doc1.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,564,669 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.24 to $16.32 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 20, 2021 Filed Dec 23, 2021 00:05 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	22,311	$15.74	$351,112.67	Disclosure SEC source: 0001567619-21-022460 · doc1.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,565,269 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.205 to $15.935 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 24, 2021 Filed Nov 25, 2021 01:48 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	30,257	$18.00	$544,580.61	Disclosure SEC source: 0001567619-21-021184 · doc1.xml · nonDerivative · entry 6 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,587,580 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.94 to $18.09 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 24, 2021 Filed Nov 25, 2021 01:48 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	25,743	$17.66	$454,703.76	Disclosure SEC source: 0001567619-21-021184 · doc1.xml · nonDerivative · entry 5 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,617,837 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.94 to $17.93 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 23, 2021 Filed Nov 25, 2021 01:48 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	2,725	$18.00	$49,050.00	Disclosure SEC source: 0001567619-21-021184 · doc1.xml · nonDerivative · entry 4 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,643,580 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.21 to $18.47 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 23, 2021 Filed Nov 25, 2021 01:48 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	53,275	$17.37	$925,637.14	Disclosure SEC source: 0001567619-21-021184 · doc1.xml · nonDerivative · entry 3 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,646,305 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.14 to $17.66 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 22, 2021 Filed Nov 25, 2021 01:48 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	646	$19.11	$12,345.06	Disclosure SEC source: 0001567619-21-021184 · doc1.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,699,580 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.02 to $19.54 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 22, 2021 Filed Nov 25, 2021 01:48 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	52,354	$18.34	$960,172.36	Disclosure SEC source: 0001567619-21-021184 · doc1.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700,226 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.01 to $19.00 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 22, 2021 Filed Oct 23, 2021 01:36 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	555	$21.16	$11,742.58	Disclosure SEC source: 0001567619-21-018627 · doc1.xml · nonDerivative · entry 10 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,752,580 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F10 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.14 to $21.21 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 22, 2021 Filed Oct 23, 2021 01:36 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	57,534	$20.74	$1,193,237.90	Disclosure SEC source: 0001567619-21-018627 · doc1.xml · nonDerivative · entry 9 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,753,135 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F9 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.12 to $21.03 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 21, 2021 Filed Oct 23, 2021 01:36 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	39	$24.50	$955.50	Disclosure SEC source: 0001567619-21-018627 · doc1.xml · nonDerivative · entry 8 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,810,669 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
October 21, 2021 Filed Oct 23, 2021 01:36 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	4,044	$23.86	$96,470.43	Disclosure SEC source: 0001567619-21-018627 · doc1.xml · nonDerivative · entry 7 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,810,708 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.38 to $24.25 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 21, 2021 Filed Oct 23, 2021 01:36 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	8,207	$23.07	$189,339.59	Disclosure SEC source: 0001567619-21-018627 · doc1.xml · nonDerivative · entry 6 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,814,752 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.37 to $23.36 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 21, 2021 Filed Oct 23, 2021 01:36 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	2,768	$21.49	$59,497.88	Disclosure SEC source: 0001567619-21-018627 · doc1.xml · nonDerivative · entry 5 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,822,959 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.30 to $21.98 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 21, 2021 Filed Oct 23, 2021 01:36 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	26,701	$20.67	$551,997.78	Disclosure SEC source: 0001567619-21-018627 · doc1.xml · nonDerivative · entry 4 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,825,727 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.22 to $21.16 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 21, 2021 Filed Oct 23, 2021 01:36 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	34,325	$19.89	$682,861.55	Disclosure SEC source: 0001567619-21-018627 · doc1.xml · nonDerivative · entry 3 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,852,428 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.21 to $20.21 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 20, 2021 Filed Oct 23, 2021 01:36 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	8,215	$25.37	$208,376.76	Disclosure SEC source: 0001567619-21-018627 · doc1.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,886,753 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.22 to $25.69 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 20, 2021 Filed Oct 23, 2021 01:36 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	22,612	$24.79	$560,531.13	Disclosure SEC source: 0001567619-21-018627 · doc1.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,894,968 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.21 to $25.21 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 07, 2021 Filed Oct 23, 2021 01:36 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	GrantCommon Stock	408,816	$0.00	$0.00	Disclosure SEC source: 0001567619-21-018627 · doc1.xml · nonDerivative · entry 14 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · As Co-Trustee of the John R. Treace Irrevocable Trust dated July 29, 2021 Disclosed balance after: 408,816 F12 · ownership.nature: The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as Trustee or Co-Trustee. Read SEC document
April 27, 2021 Filed Apr 30, 2021 01:20 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	ConversionSeries A Preferred Stock · Derivative	299,510	$0.00	$0.00	Disclosure SEC source: 0000899243-21-017486 · doc4.xml · derivative · entry 7 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 299,510 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document
April 27, 2021 Filed Apr 30, 2021 01:20 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	OtherSeries A Preferred Stock · Derivative	6,932	$0.00	$0.00	Disclosure SEC source: 0000899243-21-017486 · doc4.xml · derivative · entry 6 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,510 Underlying: Common Stock · 6,932 shares Expires not disclosed F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · derivative.exercise_price: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · derivative.exercise_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · derivative.expiration_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. Read SEC document
April 27, 2021 Filed Apr 30, 2021 01:20 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	SaleCommon Stock	5,253,805	$17.00	$89,314,685.00	Disclosure SEC source: 0000899243-21-017486 · doc4.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,917,580 F2 · kind: These shares were sold by the Reporting Person as a selling stockholder in conjuction with the Issuer's Form S-1 filing, Registration Number 333-254863. The offering closed on April 27, 2021. The reported sale price reflects the price at which the Reporting Person sold shares to the underwriters. F2 · price: These shares were sold by the Reporting Person as a selling stockholder in conjuction with the Issuer's Form S-1 filing, Registration Number 333-254863. The offering closed on April 27, 2021. The reported sale price reflects the price at which the Reporting Person sold shares to the underwriters. Read SEC document
April 27, 2021 Filed Apr 30, 2021 01:20 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	ConversionCommon Stock	299,510	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-017486 · doc4.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,171,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.